IP Library Granted Patent US 11,884,981
Granted Patent B2
US 11,884,981 · App. 17/332,225 · Granted Jan 30, 2024

Primer compositions for detecting thalassemia

Inventors: J. Francis Borgio (Dammam, SA); Sayed Abdulazeez (Dammam, SA); Fahd A. Al-Muhanna (Dammam, SA); Amein Kadhem Al-Ali (Dammam, SA)
Assignee: Imam Abdulrahman Bin Faisal University
C12Q1/6883C12Q1/686C12Q1/6806C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,981
App. No.
17/332,225
Granted
Jan 30, 2024
Kind
B2
Abstract

One aspect of the invention is a method for amplifying alpha globin genes HBA1, HBA2 and HBA12 in a single PCR tube to determine an HBA genotype of a subject. This method employs five primers selected to accurate and sensitively identify the HBA1, HBA2, and HBA12, a gene found at a higher frequency in citizens of Saudi Arabia, by accurately annealing to nucleic acids in a biological sample and simultaneously amplifying sequences encoding the alpha globin genes. This invention includes a procedure and required reagents for the amplification of alpha globin genes in a single PCR tube.

Claims (36)

1. A primer pool composition, comprising:

a set of primers for each of HBA1, HBA2 and HBA12,

wherein the set of HBA1 primers comprises MA1F (SEQ ID NO: 3) and MA12R (SEQ ID NO: 4),

the set of HBA2 primers comprises MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 2 or 6) and

the set of HBA12 primers comprises MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 2 or 6);

wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag, biotin, quencher or other detectable reporter moiety and/or by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide.

2. The primer pool composition of claim 1 , further comprising a human nucleic acid sample.

3. The primer pool composition of claim 1 , further comprising a human nucleic acid sample,

a DNA polymerase,

dNTPs,

a buffer solution, and

bivalent cations and/or monovalent cations.

4. A premarital test or other genetic test kit comprising the primer pool of claim 1 and

at least one of buccal swab(s), sample containers optionally containing preservatives for DNA, packaging materials, return mail or courier envelopes or containers, and instructions for use for assessing a risk of sickle cell anemia, sickle cell trait, or thalassemia or thalassemia trait.

5. The primer pool of claim 1 that comprises the set of HBA2 primers comprising MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 2).

6. The primer pool of claim 1 that comprises the set of HBA2 primers comprising MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 6).

7. The primer pool of claim 1 that comprises the set of HBA2 primers comprising MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 2).

8. The primer pool of claim 1 that comprises the set of HBA2 primers comprising MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 6).

9. The primer pool of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag.

10. The primer pool of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to biotin.

11. The primer pool of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a quencher.

12. The primer pool of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide.

13. The primer pool of claim 1 , wherein at least one of said HBA1, HBA2 and HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag, biotin, quencher or other detectable reporter moiety and/or by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide.

14. A primer pool composition comprising at least two primer pairs selected from the group consisting of a set of primer pairs for HBA1, HBA2 and HBA12,

wherein the set of HBA1 primers comprises MA1F (SEQ ID NO: 3) and MA12R (SEQ ID NO: 4),

the set of HBA2 primers comprises MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 2 or 6) and

the set of HBA12 primers comprises MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 2 or 6);

wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag, biotin, quencher or other detectable reporter moiety and/or by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide.

15. The primer pool composition of claim 14 , further comprising a human nucleic acid sample.

16. The primer pool composition of claim 14 , further comprising:

a human nucleic acid sample,

a DNA polymerase,

dNTPs,

a buffer solution, and

bivalent cations and/or monovalent cations.

17. A premarital test or other genetic test kit comprising the primer pool of claim 14 and at least one of buccal swab(s), sample containers optionally containing preservatives for DNA, packaging materials, return mail or courier envelopes or containers, and instructions for use for assessing a risk of sickle cell anemia, sickle cell trait, or thalassemia or thalassemia trait.

Continuity (2)
Division 16257195 · Jan 25, 2019
Related Publication 20210285051A1 · Sep 16, 2021